Composite pheochromocytoma with a malignant peripheral nerve sheath tumor: Case report and review of the literature  by Namekawa, Takeshi et al.
Asian Journal of Surgery (2016) 39, 187e190Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e-asianjournalsurgery.comCASE REPORTComposite pheochromocytoma with
a malignant peripheral nerve sheath tumor:
Case report and review of the literatureTakeshi Namekawa a, Takanobu Utsumi a,*, Takashi Imamoto a,
Koji Kawamura a, Takashi Oide b, Tomoaki Tanaka c, Naoki Nihei a,
Hiroyoshi Suzuki d, Yukio Nakatani b, Tomohiko Ichikawa aaDepartment of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
bDepartment of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan
cDepartment of Clinical Cell Biology, Graduate School of Medicine, Chiba University, Chiba, Japan
dDepartment of Urology, Toho University, Sakura Medical Center, Sakura, Japan
Received 7 August 2012; received in revised form 17 September 2012; accepted 31 October 2012
Available online 20 February 2013KEYWORDS
adrenalectomy;
adrenal tumor;
malignant peripheral
nerve sheath
tumor;
pheochromocytoma;
spontaneous rupture* Corresponding author. Department
260-8670, Japan.
E-mail address: p-cats@pd6.so-net
http://dx.doi.org/10.1016/j.asjsur.20
1015-9584/Copyright ª 2012, Asian Su
NC-ND license (http://creativecommoSummary Adrenal tumors with more than one cellular component are uncommon. Further-
more, an adrenal tumor composed of a pheochromocytoma and a malignant peripheral nerve
sheath tumor is extremely rare. A composite pheochromocytoma with malignant peripheral
nerve sheath tumor in a 42-year-old man is reported here. After adequate preoperative
control, left adrenalectomy was performed simultaneously with resection of the ipsilateral
kidney for spontaneous rupture of the left adrenal tumor. Pathological findings demonstrated
pheochromocytoma and malignant peripheral nerve sheath tumor in a ruptured adrenal tumor.
To date, there have been only four reported cases of composite pheochromocytoma with
malignant peripheral nerve sheath tumor, so the present case is only the fifth case in the
world. Despite the very poor prognosis of patients with pheochromocytoma and malignant
peripheral nerve sheath tumors reported in the literature, the patient remains well without
evidence of recurrence or new metastatic lesions at 36 months postoperatively.
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188 T. Namekawa et al.1. Introduction preoperative control, in September 2009, open left adre-The rare coexistence of a pheochromocytoma with neuro-
blastoma, ganglioneuroblastoma, ganglioneuroma, or
malignant peripheral nerve sheath tumor (MPNST) is termed
a composite pheochromocytoma.1 Bolande2 designated this
pathologic mechanism as neurocristopathy, based on the
concept that various kinds of tumors originate from devel-
opmental arrest and maldevelopment of totipotential
neural crest cells. An adrenal tumor composed of pheo-
chromocytoma and MPNST is extremely rare.1,3e5 To date,
only four cases of composite pheochromocytoma with
MPNST have been reported.1,3e5 An unusual case of
composite pheochromocytoma with MPNST in a 42-year-old
man who was treated surgically is reported here.
2. Case report
In August 2009, a 42-year-old man presented with acute left
low back pain. Abdominal and pelvic computed tomography
(CT) scan revealed an elliptic, 112 mm  88 mm2, adrenal
tumor with massive retroperitoneal hemorrhage (Fig. 1A
and B). Magnetic resonance imaging suggested an adrenal
lesion with T1 hypointensity and T2 hyperintensity. Preop-
erative serum and urinary concentrations of catecholamines
and catecholamine metabolites were as follows: serum
epinephrine 2883 pg/mL [normal range (NR) 100 pg/mL],
serum norepinephrine 36,829 pg/mL (NR 100e450 pg/mL),
serum dopamine 761 pg/mL (NR 20 pg/mL), serum
vanillylmandelic acid 43.4 ng/mL (NR 4e5 ng/mL), urinary
epinephrine 536.4 mg/d (NR 3.4e26.9 mg/d), urinary
norepinephrine 9234.0 mg/d (NR 48.6e168.4 mg/d), urinary
dopamine 289.6 mg/d (NR 365.0e961.5 mg/d), and
urinary vanillylmandelic acid 27.4 mg/d (NR 1.5e4.3 mg/d).
Other laboratory data demonstrated that this adrenal tumor
was not hormonally active except for catecholamines. On
physical examination, no evidence of neurofibromatosis type
1, such as neurofibromas over his entire skin and cafe´ au lait
spots, was found.
Finally, a definite diagnosis of a pheochromocytoma was
made based on the abovementioned results. After adequateFigure 1 Preoperative computed tomography findings showed th
(A) transverse plane and (B) coronal plane.nalectomy with simultaneous ipsilateral nephrectomy was
performed because of posthemorrhagic adhesions.
Macroscopically, the adrenal tumor appeared as a yel-
lowebrown myxoid tumor with hemorrhage and necrosis on
cross-section, measuring 90  70 mm2. Histologically, this
tumor consisted of two different components. The main
tumor cells forming predominantly zellballen-type nests
were typical of a pheochromocytoma (Fig. 2A). These
tumor cells were immunoreactive for chromogranin, syn-
aptophysin, CD56, CD57, and, focally, S100 protein.
Furthermore, separated from the domain of pheochromo-
cytoma, oval to spindle cells arranged in a streamy
fasciculated pattern (Fig. 2B). These spindle cells were
positively stained for S100 protein and were positive for Ki-
67 within the range of 10e40%. These histological findings
were consistent with the features of MPNST. Thus, we
concluded a composite pheochromocytoma with MPNST in
a ruptured adrenal tumor. Microscopic positive margins
were absent.
This patient has been followed regularly and has not
undergone any adjuvant therapy. There is no evidence of
recurrence or new metastatic lesions on CT and bone scan
at 36 months postoperatively.3. Discussion
During embryogenesis, certain cells in the neural crest
migrate ventrally and give rise to the essential cellular
components of sympathetic ganglia and adrenal medulla.3
Migration disturbance and developmental arrest or mal-
development of neural crest-derived cells may result in
various types of neoplasms.5 Bolande2 first described the
concept of neurocristopathies. Tumors composed of
various combinations of varying stages of differentiation
have been reported as part of neurocristopathies.3e5
Furthermore, in a pheochromocytoma and MPNST tumor,
sustentacular cells in the stroma of the pheochromocy-
toma have been suggested as the origin of MPNST
recently.1,4,5 Ch’ng et al1 suggested that the morpholog-
ical transition from the pheochromocytoma component toe left adrenal lesion with enhancement and large hemorrhage:
Figure 2 Histopathological examination of the adrenal specimen shows two different components: (A) pheochromocytoma
(hematoxylineeosin stain, magnification 200), and (B) malignant peripheral nerve sheath tumor (hematoxylineeosin stain,
magnification 200).
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mistry for chromogranin in the pheochromocytoma and
S100 protein in the MPNST, indicated that the MPNST was
a derivative of the former.
The MPNST component shows spindly tumor cells
arranged in a streamy fasciculated pattern with conspic-
uous compact nodules of less differentiated spindle
cells.1,3e5 The presence of S100 protein immunoreactivity
in some spindle tumor cells provides further support to the
diagnosis of MPNST.1,3e5 This case met the histological
findings that were typical of an MPNST.
Spontaneous rupture of an adrenal pheochromocytoma
has a high possibility of a lethal outcome.6e8 Kobayashi
et al6 analyzed the clinical outcomes in 50 patients with
a ruptured pheochromocytoma. Although the mortality rate
was very high in patients who could not undergo an
adequately prepared surgery, there was no mortality in
patients who underwent an elective surgery after control of
blood pressure and total circulating blood volume using a-
adrenergic blockers and fluid infusion therapy.6 In the
present case, the surgery was performed uneventfully after
adequate preoperative control, and there were no
complications in the perioperative period. We also
conclude that adequate preparation prior to surgery is theTable 1 Characteristics of five patients with pheochromocyt
patient).
Age (y) Sex Side NF-1 MP Metastasis Pathologi
confirmat
39 F L   None Operation
38 F L   Liver Operation
Retro
48 M L þ þ Lung Autopsy
Para IVC
37 F L  þ Bone, liver Autopsy
Lung, LN
42 M L   None Operation
FZ female; IVCZ inferior vena cava; LZ left; LNZ lymph node; MZ
peripheral nerve sheath tumor; NED Z no evidence of disease; NF-1most important aspect of the treatment of a ruptured
pheochromocytoma.
To the best of our knowledge, four cases of composite
pheochromocytoma with MPNST have been reported.1,3e5
Table 1 demonstrates the patients’ characteristics re-
ported in the literature and those of the present patient.
Patients with pheochromocytoma and MPNST showed a very
poor prognosis, such as cancer death or survival with
cancer. An MPNST itself is a markedly metastatic and
aggressive, poor-prognosis tumor.9 However, in the present
case, the tumor was completely removed despite
a ruptured pheochromocytoma with MPNST, and the patient
survives well without any evidence of tumor recurrence at
the present time. Zou et al9 suggested that a predictor for
local recurrence in surgically resected patients with MPNST
is positive margin status. They also showed that prognostic
factors for the development of distant metastasis and
MPNST-specific mortality in the same patients were tumor
size >10 cm and negative S100 staining.9 The present
patient can be classified as having a low risk of local
recurrence, development of distant metastasis, and
disease-specific mortality from the viewpoint of MPNST,9
although the pathological diagnosis of a malignant pheo-
chromocytoma is difficult at the present time.oma and MPNST (four from the literature and the present
cal
ion
Follow-up Report
Years Status
0.67 Cancer death Min et al3
1.5 Survival with cancer Miettinen and Saari4
0.25 Cancer death Sakaguchi et al5
28 Cancer death Ch’ng et al1
2.5 NED Present patient
male; MPZmalignant pheochromocytoma; MPNSTZmalignant
Z neurofibromatosis type 1; Retro Z retroperitoneal tumor.
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